At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10,011 enrolled
Drug / intervention
Long acting muscarinic antagonists (LAMAs) in the eveningdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparing Morning and Evening Dosing of Inhaled Long-Acting Muscarinic Antagonists for the Prevention of Hospitalization Requiring AECOPD or Death from All Causes - the LAMA by Night Study Utilizing a Comprehensive Nationwide Digital Platform for Recruitment Into a Pragmatic Randomized Controlled Trial Integrated with National Registries to Follow Outcomes
Chronic Obstructive Pulmonary Disease Trial Network, Denmark·interventional·Posted Oct 3, 2022·Updated Feb 19, 2025
In Brief
A Phase 4 clinical trial evaluating Long acting muscarinic antagonists (LAMAs) in the evening for COPD Exacerbation. Completed, enrolled 10,011 participants across 1 site.
Detailed Summary
To examine, among once-daily LAMA using COPD patients, whether evening administration of LAMA is superior with respect to the incidence of hospitalization requiring AECOPD or death from all causes than the more conventional morning administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD Exacerbation
CountriesDenmark
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartJan 2023
Primary CompletionJun 2024
TodayJul 2026
First PostedOct 3, 2022
Enrollment StartJan 27, 2023
Primary CompletionJun 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.7 years ago
Interventions
Long acting muscarinic antagonists (LAMAs) in the eveningdrug
LAMAs administered at bedtime (8pm - 2am)